Background: With its growing popularity and potential outcome, preoperative three-dimensional reconstruction of chest computed tomography (CT) has been widely used in video-assisted thoracic surgery (VATS) segmentectomy for treating non-small cell lung cancer (NSCLC). This study aimed to summarize the experience of anatomical variation analysis of left upper pulmonary blood vessels and bronchi based on the three-dimensional reconstruction of chest CT.Materials and methods: A total of 103 patients with early-stage NSCLC were chosen to undergo VATS segmentectomy based on preoperative three-dimensional reconstruction of chest CT in our institute from September 2019 to July 2022. Data such as clinical characteristics and variations in blood vessels and bronchi were reviewed in this study.Results: The branches of the left lingular pulmonary artery may mutate into the LS1 + 2 + 3. A1 + 2 has four subtypes. The distribution of variation is relatively balanced, and the most common variation is type I (35/103, 33.9%). Most lingular arteries originate from the oblique cleft side of the lingular bronchus (79/103,76.7%). Most V(1 + 2)c* are small developments (70/103, 68.0%). The venous return of the proper segment mainly depends on V(1 + 2)b + c. The variation in the left upper lobe bronchus is complex. The most common variant is the bifurcation type (type A to G, 92/103, 89.3%) and bifurcation type A (62/103, 60.2%). The posterior apical segment artery of the left upper lobe is not accompanied by its bronchus.Conclusions: The variation types of blood vessels and bronchus in the upper lobe of the left lung are complex. Preoperative CT-based three-dimensional reconstruction of pulmonary arteries, veins, and bronchi is of great significance. It can help understand the variations, accurately locate lesions before the surgery, and effectively plan surgeries.
27 November 2024 in Clinical and Translational Medicine
Background: The increasing prevalence of multiple primarylung cancers (MPLCs) presents challenges to current diagnostic and clinicalmanagement approaches. However, the molecular mechanisms driving MPLCdevelopment and distinguishing it from solitary primary lung cancers (SPLCs)remain largely unexplored.Methods: We performed a comparative single‐cell RNAsequencing (scRNA‐seq) analysis on tumour and adjacent para‐tumour tissues fromMPLC and SPLC patients to comparatively evaluate their immunological landscapes.Additionally, multiplex immunofluorescence (mIF) staining and independentvalidation datasets were used to confirm findings.Results: MPLCs and SPLCs share significant similarities in genetic, transcriptomic and immune profiles, suggesting common therapeutic strategies such as EGFR‐TKIs andICIs. Notably, an immunosuppressive macrophage subtype, F13A1+ Macrophage (Mϕ), is specifically enriched in MPLCs. This subtype overexpresses M2 macrophagemarkers and exhibits up‐regulation of SPP1‐CD44/CCL13‐ACKR1 interactions, indicatingits role in shaping the immunosuppressive tumour microenvironment and promotingtumour growth in MPLCs.Conclusions: This study unveils shared molecular mechanismsbetween MPLCs and SPLCs, while identifying MPLC‐specific cellular and molecularfeatures, such as the role of F13A1+ macrophages. The findings provide novelinsights into MPLC pathogenesis, supporting the development of targetedtherapeutic strategies.Key points: Comparative scRNA‐seq analysis reveals significant similarities in genetic, transcriptomicand immune profiles between MPLCs and SPLCs. Identification of a unique immunosuppressive F13A1+ macrophage subtype, preferentially enriched in MPLCs, linked to immune evasion and tumourprogression. SPP1‐CD44/CCL13‐ACKR1 interactions are crucial in MPLC tumour microenvironment, indicating potential targets for therapeutic intervention.
Nonsmall cell lung cancer (NSCLC) with SMARCA4 deficiency represents a rare subset of lung tumors characterized by early metastasis, poor response to chemotherapy, and unfavorable prognosis. Established therapy strategies for SMARCA4-deficient NSCLC remain elusive. While immune checkpoint inhibitors have been proposed as a potential solution, their efficacy remains uncertain. Clinical factors such as tumor mutational burden (TMB), microsatellite instability, comutations, and programmed death-ligand 1 (PD-L1) expression may influence the treatment response of SMARCA4-deficient NSCLC. Additionally, PD-L1 expression on circulating tumor cells (CTCs) provides novel insights for monitoring, and its utility in SMARCA4-deficient NSCLC remains unexplored. The present report describes the case of a 71-year-old man diagnosed with SMARCA4-deficient NSCLC who had a history of heavy smoking and chronic cough. Imaging examination revealed metastatic lymph nodes. All serum tumor markers were elevated above the normal range. Histopathological and immunohistochemical analyses of the biopsy specimen from a primary lesion in the right upper lung demonstrated irregularly arranged tumor cells, SMARCA4 deficiency, and positive PD-L1 expression. Further next-generation sequencing confirmed SMARCA4 mutation, high TMB, and microsatellite stability (MSS). The patient received pembrolizumab treatment and experienced a sustained benefit for >40 months, with persistent PD-L1 expression on CTCs observed throughout the treatment. It was revealed that pembrolizumab therapy shows promise for patients with SMARCA4-deficient NSCLC with positive PD-L1 expression, high TMB, and MSS. Dynamic monitoring of PD-L1 status on CTCs may facilitate the assessment of the immunotherapy response, and the sustained positive PD-L1 expression on CTCs may imply continued benefit from immunotherapy for patients with SMARCA4-deficient NSCLC.
The vital regulation of abnormally expressed lncRNAs in human cancers has been identified. This study is aimed at illustrating the role of LINC01426 in influencing malignant behaviors of lung adenocarcinoma (LUAD) and the possible mechanism. Differential expressions of LINC01426 in a downloaded profile containing LUAD and normal tissues were analyzed using Gene Expression Profiling Interactive Analysis (GEPIA) database and were reconfirmed in clinical samples collected in our hospital. In addition, LINC01426 level in lung carcinoma cell lines was detected by quantitative real‐time polymerase chain reaction (qRT‐PCR) as well. The relationship between LINC01426 expression and the age, tumor node metastasis (TNM) staging, lymphatic metastasis, tumor differentiation, and overall survival of LUAD was analyzed. After intervening LINC01426 level in H1299 and PC9 cells, proliferative and metastatic changes were assessed by functional experiments. LINC01426 was upregulated in LUAD tissues and cell lines. Its level was closely linked to TNM staging, lymphatic metastasis, tumor differentiation, and overall survival of LUAD. Knockdown of LINC01426 suppressed proliferative and metastatic abilities in H1299 and PC9 cells. LINC01246 is upregulated in LUAD samples and predicts a poor prognosis. It drives malignant process of LUAD via stimulating proliferative and metastatic abilities.
Background: Although multiple studies have confirmed that adjusting the time-of-day (ToDA) of immunotherapy and timing interval (TI) of chemoimmunotherapy can improve long-term outcomes in patients with advanced non-small cell lung cancer (NSCLC), whether this model similarly improves survival among patients with operable NSCLC has not been reported. Patients and methods: This dual-center, retrospective study included adult patients who received neoadjuvant chemoimmunotherapy (neoCIT) for clinical stage T1-4N0-3M0 NSCLC between January 2019 and December 2024. The impact of the ToDA of neoadjuvant immunotherapy (neoIO) on the efficacy and safety were analyzed. In addition, the inverse probability of treatment weighting (IPTW)-weighted Cox regression model was used to compare disease-free survival (DFS) and overall survival (OS) between patients who received either ≥75% (≥75% group) or <75% (<75% group) of the neoIO administrations before 14:00 h. Results: A total of 168 consecutive patients with a median follow-up of 30.3 months were included, of whom 123 patients (73.2%) were in the ≥75% group. Neoadjuvant treatment-related adverse events (neoTRAEs) occurred in 47.6% of the patients, including 63 (51.2%) and 17 (37.8%) patients in the ≥75% and <75% groups, respectively ( P = 0.122). Pathologic complete response occurred in 31.7% of the patients in the ≥75% group and in 20.0% of those in the <75% group ( P = 0.177); major pathologic response occurred in 59.3% and 48.9%, respectively ( P = 0.300). According to the results of the IPTW-weighted univariate Cox analysis, patients in the <75% group had worse 3-year rates of DFS (77.1% vs. 77.9%; P = 0.065) and OS (68.3% vs. 89.1%; P = 0.033). These findings remained robust to multivariate Cox regression models (DFS: hazard ratio [HR]ffoo, 2.858; 95% confidence intervals [CIs]: 1.239-6.692; P = 0.014; and OS: HR, 7.625; 95% CIs: 1.112-52.272; P = 0.039). Additionally, a shorter mean TI of patients who received neoCIT infusions (<23.5 vs. ≥23.5 hours) emerged as an independent factor associated with better OS (HR, 0.143; 95% CIs, 0.024-0.875; P = 0.035). Conclusions: Although early infusions of most neoIO drugs did not affect safety or efficacy, it showed a potential trend toward improving long-term survival. The corresponding immune microenvironment and molecular mechanisms need further exploration to guide the design of future prospective clinical studies.